• 1
    Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med 1989; 169: 493502.
  • 2
    Sykes M, Szot GL, Swenson KA, Pearson DA. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nat Med 1997; 3: 783787.
  • 3
    Huang CA, Fuchimoto Y, Scheier-Dolberg R, Murphy MC, Neville DM, Jr. Sachs DH. Stable mixed chimerism and tolerance using a nonmyeloablative preparative regimen in a large-animal model. J Clin Invest 2000; 105: 173181.
  • 4
    Kawai T, Cosimi AB, Colvin RB et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgous monkeys. Transplantation 1995; 59: 256262.
  • 5
    Kimikawa M, Sachs DH, Colvin RB, Bartholemew A, Kawai T, Cosimi AB. Modifications of the conditioning regimen for achieving mixed chimerism and donor-specific tolerance in cynomolgus monkeys. Transplantation 1997; 64: 709716.
  • 6
    Sykes M, Sheard MA, Sachs DH. Graft-versus-host-related immunosuppression is induced in mixed chimeras by alloresponses against either host or donor lymphohematopoietic cells. J Exp Med 1988; 168: 23912396.
  • 7
    Pelot MR, Pearson DA, Swenson K et al. Lymphohematopoietic graft-vs-host reactions can be induced without graft-vs-host disease in murine mixed chimeras established with a cyclophosphamide-based non-myeloablative conditioning regimen. Biol Blood Marrow Transplant 1999; 5: 133143.
  • 8
    Mapara MY, Kim Y-M, Marx J, Sykes M. DLI-mediated GVL effects in mixed chimeras established with a non-myeloablative conditioning regimen: Extinction of GVL effects coincides with loss of alloreactive cells following conversion to full donor chimerism. Transplantation 2003; 76: 297305.
  • 9
    Mapara MY, Kim Y-M, Wang S-P, Bronson R, Sachs DH, Sykes M. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: A critical role for host antigen-presenting cells. Blood 2002; 100: 19031909.
  • 10
    Spitzer TR, MCafee S, Sackstein R et al. The intentional induction of mixed chimerism and achievement of anti-tumor responses following non-myeloablative conditioning therapy and HLA-matched and mismatched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 2000; 6: 309320.
  • 11
    Spitzer TR, MCafee S, Dey BR et al. Non-myeloablative haploidentical stem cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies. Transplantation 2003; 75: 17481751.
  • 12
    Dey BR, MCafee S, Sackstein R et al. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 604612.
  • 13
    Dey BR, MCafee S, Colby C et al. Impact of prophlactic donor leukocyte infusions on mixed chimerism, graft-vs-host disease and anti-tumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2003; 9: 320329.
  • 14
    Lenhoff S, Hjorth M, Holmberg E et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population-based study. Nordic Myeloma Study Group. Blood 2000; 95: 711.
  • 15
    Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: Proof of principle. Blood 1996; 87: 11961198.
  • 16
    Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LL, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997; 90: 42064211.
  • 17
    Bjorkstrand BB, Ljungman P, Svensson H et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996; 88: 47114718.
  • 18
    Spitzer TR, Delmonico F, Tolkoff-Rubin N et al. Combined HLA-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: The induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999; 68: 480484.
  • 19
    Buhler LH, Spitzer TR, Sykes M et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation 2002; 74: 14051409.
  • 20
    Sykes M, Preffer F, McAfee S et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 1999; 353: 17551759.
  • 21
    Inoue CN, Kondo Y, Ohnuma S, Morimoto T, Nishio T, Iinuma K. Use of cultured tubular cells isolated from human urine for investigation of renal transporter. Clin Nephrol 2000; 53: 9098.
  • 22
    Racusen LC, Monteil C, Sgrignoli A et al. Cell lines with extended in vitro growth potential from human renal proximal tubule: Characterization, response to inducers, and comparison with established cell lines. J Lab Clin Med 1997; 129: 318329.
  • 23
    Koenecke C, Shaffer J, Alexander S et al. NK cell recovery, chimerism, function and recognition in recipients of haploidentical hematopioetic cell transplantation following non-myeloablative conditioning using a humanized anti-CD2 mAb, Medi-507. Exp Hematol 2003; 31: 911923.
  • 24
    Kraus AB, Shaffer J, Toh HC et al. Early host CD8 T-cell recovery and sensitized anti-donor IL-2-producing and cytolytic T-cell responses associated with marrow graft rejection following nonmyeloablative bone marrow transplantation. Exp Hematol 2003; 31: 609621.
  • 25
    Bonnefoix T, Bonnefoix P, Perron P et al. Quantitating effector and regulatory T lymphocytes in immune responses by limiting dilution analysis modeling. J Immunol 2005; 174: 34213431.
  • 26
    Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens [see comments]. Blood 1999; 93: 23362341.
  • 27
    Buszello H, Ackermann R. Expression of HLA class-I antigens on renal cell carcinoma and non-transformed renal tissue. Eur Urol 1992; 21: 7074.
  • 28
    Beck Y, Sekimata M, Nakayama S et al. Expression of human minor histocompatibility antigen on cultured kidney cells. Eur J Immunol 1993; 23: 467472.
  • 29
    Kim YM, Mapara MY, Down JD et al. Graft-versus-host-reactive donor CD4 cells can induce T cell-mediated rejection of the donor marrow in mixed allogeneic chimeras prepared with nonmyeloablative conditioning. Blood 2004; 103: 732739.
  • 30
    Dey BR, MCafee S, Colby C et al. Anti-tumor response despite loss of donor chimerism in patients treated with nonmyeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 2005; 128: 351359.
  • 31
    O'Donnell PV, Luznik L, Jones RJ et al. Nonmyeloablative bone marrow transplantation from partially HLA- mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002; 8: 377386.
  • 32
    Rubio MT, Kim YM, Sachs T, Mapara M, Zhao G, Sykes M. Anti-tumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: Critical role for recipient-derived IFN-{gamma}. Blood 2003; 102: 23002307.
  • 33
    Rubio MT, Saito TI, Kattelman K, Zhao G, Buchli J, Sykes M. Mechanisms of the anti-tumor responses and host-versus graft reactions induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: A critical role for recipient CD4+ T cells and recipient leukocyte infusion-derived IFN-gamma-producing CD8+ T cells. J Immunol 2005; 175: 665676.
  • 34
    Lefkovits I, Waldmann H. Limiting Dilution Analysis of Cells of the Immune System. 2nd Ed. Oxford , Oxford University Press, 1999.
  • 35
    Bonnefoix T, Bonnefoix P, Mi JQ, Lawrence JJ, Sotto JJ, Leroux D. Detection of suppressor T lymphocytes and estimation of their frequency in limiting dilution assays by generalized linear regression modeling. J Immunol 2003; 170: 28842894.
  • 36
    Eichmann K, Falk I, Melchers I, Simon MM. Quantitative studies on T cell diversity. I. Determination of the precursor frequencies for two types of streptococcus A specific helper cells in non-immune, polyclonally activated splenic T cells. J Exp Med 1980; 152: 477492.
  • 37
    Eichmann K, Goronzy J, Hamann U et al. Clonal analysis of helper and cytolytic T cells: Multiple, independently regulated precursor sets at frequencies suggesting a limited repertoire. In Isolation, Characterization, and Utilization of T Lymphocyte Clones. Academic Press, 1982: 233244.
  • 38
    Parrado A, Casares S, Prieto J, Carmona M, Vaquero A, Rodriguez-Fernandez JM. Repopulation of circulating T, B and NK lymphocytes following bone marrow and blood stem cell transplantation. Hematol Cell Ther 1997; 39: 301306.
  • 39
    Davison GM, Novitzky N, Kline A et al. Immune reconstitution after allogeneic bone marrow transplantation depleted of T cells. Transplantation 2000; 69: 13411347.
  • 40
    Roberts MM, Lo LB, Gillis D et al. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation. Bone Marrow Transplant 1993; 12: 469475.
  • 41
    Collins AB, Schneeberger EE, Pascual MA et al. Complement activation in acute humoral renal allograft rejection: Diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999; 10: 22082214.
  • 42
    Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria—an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708714.
  • 43
    Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713723.
  • 44
    Schmidtko J, Wang R, Wu CL et al. Posttransplant lymphoproliferative disorder associated with an Epstein- Barr-related virus in cynomolgus monkeys. Transplantation 2002; 73: 14311439.
  • 45
    Taswell C. Limiting diluton assays for the determination of immunocompetent cell frequencies. III. Validity tests for the single-hit Poisson model. J Immunol Methods 1984; 72: 2940.